We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Honeybee Peptide Helps To Deliver Therapeutic Proteins
News

Honeybee Peptide Helps To Deliver Therapeutic Proteins

Honeybee Peptide Helps To Deliver Therapeutic Proteins
News

Honeybee Peptide Helps To Deliver Therapeutic Proteins

An orange-red dye shows that blood clots formed in a mouse ear in which thrombin was released from light-triggered RBCs. Scale bar, 50 μm. Credit: Adapted from ACS Central Science 2020, DOI: 10.1021/acscentsci.0c01151
Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Honeybee Peptide Helps To Deliver Therapeutic Proteins "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Protein therapies are often more potent and selective toward their biochemical targets than other types of drugs, particularly small molecules. However, proteins are also more likely to be quickly degraded by enzymes or cleared from blood by the kidneys, which has limited their clinical use. Now, researchers reporting in ACS Central Science have engineered red blood cell (RBC) carriers that release therapeutic proteins when stimulated by light, with the help of a honey bee peptide.

Because protein drugs are unstable in the body, they must be given at high levels, which can cause side effects. Scientists have tried to protect protein therapies from degradation by encapsulating them in carriers, such as liposomes, nanoparticles and RBCs. But it has been challenging to make the carriers release their cargo at the appropriate place and time. Brianna Vickerman, David Lawrence and colleagues wanted to engineer RBCs to release therapeutic proteins at specific regions of the body when triggered by certain wavelengths of light.

The researchers embedded a peptide, called melittin, into the cell membrane of RBCs. A component of European honey bee venom, melittin normally causes RBCs to rupture. But the team modified the peptide so that it would do so only when illuminated by a specific wavelength of light. As a proof of concept, the researchers loaded thrombin –– a blood-clotting enzyme that is used to prevent excessive bleeding –– into the engineered RBCs and injected them into mice. They then shone a light on a small region of each mouse’s ear and examined sections of the tissue. The analysis showed thrombin-related blood clotting only at the illuminated sites. The strategy could prove useful for the light-triggered release of protein, peptide and nucleic acid therapeutics from a variety of lipid-based carriers, the researchers say.

Reference: Vickerman BM, O’Banion CP, Tan X, Lawrence DS. Light-controlled release of therapeutic proteins from red blood cells. ACS Cent Sci. 2020. doi:10.1021/acscentsci.0c01151

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Advertisement